JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis
Arthritis & Rheumatology2018Vol. 70(12), pp. 1959–1970
Citations Over TimeTop 10% of 2018 papers
Trudy McGarry, Carl Orr, S Wade, Monika Biniecka, Siobhan Wade, Lorna Gallagher, Candice Low, Douglas J. Veale, Ursula Fearon
Abstract
This study demonstrates that JAK/STAT signaling mediates the complex interplay between inflammation and cellular metabolism in RA pathogenesis.
Related Papers
- → FDA approves tofacitinib for rheumatoid arthritis(2012)97 cited
- → Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies(2016)31 cited
- → The off-label uses profile of tofacitinib in systemic rheumatic diseases(2020)13 cited
- → P088 REAL-WORLD EXPERIENCE WITH TOFACITINIB FOR THE MANAGEMENT OF CROHN’S COLITIS(2020)2 cited
- → AB0344 FACTORS WHICH CONTRIBUTE PERSISTENCY AND OPTIMAL USE OF TOFACITINIB; LESSONS FROM LONG TERM DAILY CLINICAL USE OF TOFACITINIB(2020)